Material Event Form 8 K

Item 8.01Other Events.

In December 2022, SeaStar Medical Holding Corporation (the "Company") entered into a license and distribution agreement (the "Distribution Agreement") with Nuwellis, Inc. ("Nuwellis"), pursuant to which the Company appointed Nuwellis as its exclusive distributor for the sale and distribution of its pediatric SCD product throughout the United States. In May 2024, the Company provided notice to Nuwellis that Nuwellis had breached the Distribution Agreement and that the Distribution Agreement would terminate effective August 18, 2024.

Nuwellis disputed the validity of the termination and on October 20, 2024, the Company entered into a confidential settlement agreement and release with Nuwellis, pursuant to which the Company agreed to pay Nuwellis an aggregate of $900,000 payable in three installments through December 31, 2024.